
Atherothrombosis
Discover more on science updates, events, KOLs interviews and more on Atherothrombosis
Science in Atherothrombosis
Get a 360º view and stay up-to-date on Atherothrombosis with content selected for you

- Atherothrombosis
- Cardiovascular
- Atherothrombosis
No Rebound Effect Post Clopidogrel Withdrawal

- Atherothrombosis
Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice

- Atherothrombosis
In hospital outcomes in young patients with AMI: Results from Gulf Coast

- Atherothrombosis
Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

- Atherothrombosis
Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?
Inspiration and innovation
Get inspired and stay at the forefront of innovation with the following resources

- Atherothrombosis
- Cardiovascular
- Atherothrombosis
No Rebound Effect Post Clopidogrel Withdrawal
.webp/jcr:content/dapt-thumb%20(3).webp)
- Atherothrombosis
- Atherothrombosis
DAPT in Elderly with CAD Meta Analysis
Watch the video and get to know more on the crucial insights from this systematic review and meta-analysis of DAPT in elderly patients with acute coronary syndrome (ACS). Dual oral antiplatelet therapy (DAPT) with prasugrel or ticagrelor is associated with a higher risk of bleeding events in elderly patients with ACS compared to clopidogrel, with no difference in primary efficacy endpoint rates between the treatment groups.

- Atherothrombosis
- Atherothrombosis
Clopidogrel as the standard of care for elective PCI: Findings from the Alpheus

- Atherothrombosis
- Atherothrombosis